Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15103889 | 0.82 | CRHR1 (0.58) | CRHR1TSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL15104032 | 0.82 | CRHR1 (0.53) | CRHR1TSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL545900 | 0.80 | CRHR1 (0.50) | CRHR1TSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL4693477 | 0.71 | CRHR1 (0.67) | CRHR1MAPTKDM4EUSP2ALDH1A1 | |
| SCHEMBL4693619 | 0.71 | CRHR1 (0.67) | CRHR1MAPTKDM4EUSP2ALDH1A1 | |
| SCHEMBL3963171 | 0.69 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL4695461 | 0.68 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL4690737 | 0.67 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL545442 | 0.67 | CRHR1 (0.38) | CRHR1HPGD | |
| SCHEMBL545659 | 0.67 | CRHR1 (0.39) | CRHR1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076515-B1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8110580-B2 | Thiophene pyrazolopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CHEN ZHAOGEN | 2010-01-28 | — | — | US | disclosed |
| EP-2076515-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008036541-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022560-A1 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS | CRH, CRHR1, CRHR2 | CRHR1 2/4885TSHR 51/4885MAPT 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.